| Identification | Back Directory | [Name]
2-AzetidinecarboxaMide, N-[[4-(aMinoiMinoMethyl)phenyl]Methyl]-1-[(2R)-2-[3-chloro-5-(difluoroMethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- | [CAS]
433937-74-7 | [Synonyms]
ARH067637
AR-H067637
AR H067637
ARH067637,AR H067637,AR-H-067637
(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]azetidine-2-carboxamide
2-AzetidinecarboxaMide, N-[[4-(aMinoiMinoMethyl)phenyl]Methyl]-1-[(2R)-2-[3-chloro-5-(difluoroMethoxy)phenyl]-2-hydroxyacetyl]-, (2S)- | [Molecular Formula]
C21H21ClF2N4O4 | [MDL Number]
MFCD27665463 | [MOL File]
433937-74-7.mol | [Molecular Weight]
466.87 |
| Hazard Information | Back Directory | [Uses]
Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders[1]. | [References]
[1] Deinum J, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009 Jun;101(6):1051-9. PMID:19492147 |
|
|